Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VQW-765 in Social Anxiety Disorder
NCT07221578Phase 3Active, not recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AQW051 in Social Anxiety Disorder (SAD), sponsored by Vanda Pharmaceuticals Inc.. Started Sep 2025; status: active, not recruiting.
02
Drugs
AQW051
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT07221578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221578.